Clinical Trial Update: A Phase 1 of CTX-8371 in Patients With Advanced Malignancies [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating CTX-8371 in patients with advanced malignancies, including Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer, curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Hodgkin Lymphoma
• Malignant Melanoma
• Non-small Cell Lung Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• CTX-8371

Snippet

Sponsor: Compass Therapeutics | Conditions: Non Small Cell Lung Cancer, Triple Negative Breast Cancer | Phase 1 | Status: RECRUITING